Spots Global Cancer Trial Database for Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Official Title: Randomized, Double-blind Phase 2 Study Of Axitinib (Ag-013736) With Or Without Dose Titration In Patients With Metastatic Renal Cell Carcinoma
Study ID: NCT00835978
Conditions
Study Description
Brief Summary: Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
East Bay Medical Oncology/Hematology Medical Associates Inc., Antioch, California, United States
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Bay Area Cancer Research Group, LLC, Pleasant Hill, California, United States
Diablo Valley Oncology and Hematology Medical Group Inc, Pleasant Hill, California, United States
East Bay Medical Oncology/Hematology Medical Associates Inc, Pleasant Hill, California, United States
East Bay Medical Oncology/Hematology Medical Associates Inc, San Leandro, California, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Investigational Drug Services, IUHSCC, Indianapolis, Indiana, United States
IU Health University Hospital, Indianapolis, Indiana, United States
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Washington University, Saint Louis, Missouri, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Nevada Cancer Institute, Las Vegas, Nevada, United States
The University Hospital, Cincinnati, Ohio, United States
University of Cincinnati, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
The Ohio State University, James Cancer Hospital, Columbus, Ohio, United States
JamesCare in Kenny, Columbus, Ohio, United States
West Chester Hospital Medical Building, West Chester, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
Texas Oncology, Sammons Cancer Center, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Virginia Mason Medical Center, Seattle, Washington, United States
Masarykuv onkologicky ustav, Brno, CZE, Czechia
Fakultni nemocnice Olomouc Onkologicka klinika, Olomouc, , Czechia
Fakultni nemocnice Na Bulovce, Praha 8, , Czechia
Krajska zdravotni, a.s. - Masarykova nemocnice V Usti nad Labem, o.z., Usti nad Labem, , Czechia
Universitaetsklinikum Duesseldorf, Duesseldorf, , Germany
Klinikum der J. W. Goethe-Universitaet, Medizinische Klinik II, Frankfurt, , Germany
Medizinische Hochschule Hannover, Abt. Haematologie, Haemostaseologie & Onkologie, Hannover, , Germany
Eberhardt-Karls-Universitaet Tuebingen, Klinik fuer Urologie, Tuebingen, , Germany
Klinikum Weiden Klinik fuer Urologie, Andrologie und Kinderurologie, Weiden, , Germany
Nagoya University Hospital, Nagoya, Aichi, Japan
Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Kobe University Hospital, Kobe, Hyogo, Japan
Kinki University Hospital, Osakasayama, Osaka, Japan
Hamamatsu University School of Medicine, University Hospital, Hamamatsu-City, Shizuoka, Japan
National Cancer Center, Chuo-ku, Tokyo, Japan
Japanese Foundation For Cancer Research Cancer Institute Hospital, Koto-ku, Tokyo, Japan
Keio University Hospital, Shinjuku-ku, Tokyo, Japan
Akita University Hospital, Akita, , Japan
Chiba Cancer Center, Chiba, , Japan
Kyushu University Hospital, Fukuoka, , Japan
Nagasaki University Hospital, Nagasaki, , Japan
Tokushima University Hospital, Tokushima, , Japan
Yamagata University Hospital, Yamagata, , Japan
Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia, Obninsk, Kaluga Region, Russian Federation
State Healthcare Institution "Leningrad Regional Oncology Dispensary", Poselok Kuzmolovskiy, Vsevolozhskiy Region, Leningradskaya Oblast, Russian Federation
FSBSI "N.N. Blokhin Russian Cancer Research Center", Moscow, , Russian Federation
FSBI"Russian Scientific Center of Roengenoradiology" of the MH of RF, Moscow, , Russian Federation
Saint-Petersburg's State Healthcare Institution 'City Clinical Oncology Dispensary', Saint-Petersburg, , Russian Federation
Saint-Petersburg's State Healthcare Institution 'City Clinical Oncology Dispensary', Saint-Petersburg, , Russian Federation
GBUZ "Samara Regional Clinical Oncology Dispensary", Samara, , Russian Federation
Hospital de La Princesa, Madrid, , Spain
Hospital General Universitario Gregorio Marañon, Madrid, , Spain
Hospital Universitario La Paz, Madrid, , Spain
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
